Mirtazapine Rosemont Pharmaceuticals

Mirtazapine, the active ingredient in Mirtazapine Rosemont Pharmaceuticals, is a tetracyclic antidepressant presented as an unspecified strength/tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapine Rosemont Pharmaceuticals as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a tetracyclic antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depressive episodes in bipolar disorder (adjunct): helps alleviate depressive phases when used with mood stabilisers. - Depression with insomnia: promotes sleep and may improve appetite, aiding recovery.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction or jaundice - Suicidal thoughts or behavior - Severe rash or Stevens‑Johnson syndrome - Seizures - Hyponatraemia

Before initiating therapy, clinicians should consider several safety measures.

- Assess suicidality: monitor patients for worsening depression or emergence of suicidal thoughts. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal symptoms. - Caution in hepatic impairment: dose adjustment may be required. - Use with caution in elderly: increased risk of sedation and falls. - Avoid concomitant MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase mirtazapine plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance central nervous system depression. - Other CNS depressants (e.g., benzodiazepines): additive sedation. - Anticoagulants (e.g., warfarin): potential increase in bleeding risk.